Plasma epinephrine (pg/ml)
| Basal | After maze | |
|---|---|---|
| Euglycemic | ||
| Nondiabetic | ||
| Control | 58 ± 4 | 110 ± 20 |
| RH | 63 ± 3 | 142 ± 32 |
| Diabetic | ||
| Control | 51 ± 6 | 160 ± 28 |
| RH | 49 ± 8 | 124 ± 21 |
| Hypoglycemic | ||
| Nondiabetic | ||
| Control | 65 ± 5 | 4,986 ± 539* |
| RH | 75 ± 13 | 1,611 ± 363* |
| Diabetic | ||
| Control | 72 ± 7 | 3,010 ± 695*‡ |
| RH | 83 ± 12 | 890 ± 293*†‡ |
Plasma epinephrine concentrations, taken both at baseline (basal) and immediately after completion of maze testing.
* Significant increase in after-maze versus basal samples;
† significant effect of RH (epinephrine decreased versus controls);
‡ significant effect of diabetes (epinephrine decreased versus nondiabetics).